Lepor, Norman

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 2,296

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

Nissen, S. E., Stroes, E., Dent-Acosta, R. E., Rosenson, R. S., Lehman, S. J., Sattar, N., Preiss, D., Bruckert, E., Ceška, R., Lepor, N., et al. (2016) · JAMA

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 522

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

Ballantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 422

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Bhatt, D. L., Steg, P. G., Mehta, S. R., Leiter, L. A., Simon, T., Fox, K., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 209

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., Jukema, J. W., Landmesser, U., López-Jaramillo, P., Manvelian, G., Pordy, R., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 150

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 118

Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study

Hovingh, G. K., Lepor, N. E., Kallend, D., Stoekenbroek, R. M., Wijngaard, P. L. J., & Raal, F. J. (2020) · Circulation

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 113

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 64

A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide

Navar, A. M., Mikhailova, E., Catapano, A. L., Banka, P., Blom, D. J., Cadena, A., Kourpanidis, S., Lepor, N. E., Tsukamoto, K., Mendizabal, G., et al. (2026) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 57